CD8A and neoplasm: To verify this hypothesis, we set up an in vitro immunotoxicity test to demonstrate that monocytes preloaded with the custom antigen can transfer the corresponding pMHC-I complex via MV trafficking to tumor cells, which is a necessary and sufficient condition for the acceptor cells to be the target of the cytotoxic action of CD8+ lymphocytes (Tables 1–3).